Type 2 Diabetes, Foot Ulcers and Cognition

Summary:  Research group finds that type 2 diabetics with foot ulcers possess fewer cognitive resources than a matched group of type 2 diabetics without foot ulcers.

The harmful impact of diabetes on peripheral and central nervous system functioning is well documented. Peripherally, approximately 50% of people suffering from diabetes will, over the course of the disease, develop diabetic polyneuropathy, the most common form of diabetic peripheral neuropathy.  The harmful impact of diabetes on the central nervous system is also well established. Diabetes is a risk factor for cognitive decline.  In fact, some researchers classify Alzheimer’s Disease as Type 3 diabetes.

There is a well-established correlation between the increased severity of polyneuropathy—with the accompanying loss of protective sensation—and diabetic foot ulcers. Now an Israeli research group has found a correlation between diabetic foot ulcers and decreased cognitive ability.  Their work, “Cognitive Dysfunction: Part and Parcel of the Diabetic Foot”, was published in 2016 in the journal Diabetes Careand concluded that type 2 diabetics with foot ulcers possess fewer cognitive resources than a matched group of type 2 diabetics without foot ulcers.

Does this newly discovered relationship—between decreased cognitive ability and foot ulcers in type 2 diabetics—reflect a greater level of generalized neurological dysfunction—both peripheral and central—in these patients? Or are these patients, alternatively, unable to appreciate the long-term consequences of foot ulcers—and thus engage in activities that put their feet at heightened risk because they are unable to recognize the importance of adequately protecting their feet?

In any case, these patients may struggle to complete tasks that require greater cognitive resources, such as following complicated instructions or performing self-treatment regimens. As a result, clinicians may want to account for these possible struggles when caring for type 2 diabetics with foot ulcers.

A request from the author:
Have any of your patients who have taken NeuRemedy experienced any benefits in addition to improvement in their neuropathic symptoms? If so, I would like to know. Please contact me at rhm123@gmail.com or call me at 561-549-9099.

Dr. Mann bust-shot

Dr. Richard H Mann, DABPS, ret
Chief Scientific Officer & Founder, Realm Labs

If you would like to speak with Dr. Mann about how to improve your outcomes in the treatment of polyneuropathy call 866-634-2745 or email Dr. Mann at realmlabs123@gmail.com

Dr. Mann is the developer of the  NeuRemedy®line of benfotiamine nutritional supplements. NeuRemedy is a safe, proven, and effective nutritional formulation dispensed by physicians to their patients suffering from numbness, tingling, burning and/or shooting pains in the feet and legs.  Thiamine (vitamin B1) deficiency often accompanies and intensifies these symptoms. The reversal of thiamine deficiency is an important therapeutic goal in the management of these patients.*

The key ingredient in NeuRemedy, benfotiamine, is the most highly bioactive oral form of thiamine available. It rapidly and safely reverses thiamine deficiency, improving the functioning of the nerves in the feet and legs. Each capsule of NeuRemedy contains 150 mg of benfotiamine in a proprietary formulation. Because of its impressive success rate and high safety profile, NeuRemedy was recently licensed in Canada as an important factor in supporting healthy nerve function in individuals with polyneuropathy.*

NeuRemedy is the leader in the field with thousands of physicians and patients relying each day on its efficacy, purity, safety and rapid onset of action.*

For more information on NeuRemedy:
In the USA, contact Realm Labs at 866-634-2745.
In Canada contact OHI at 855-561-4156.

Leave a Reply